See more : PT Pudjiadi Prestige Tbk (PUDP.JK) Income Statement Analysis – Financial Results
Complete financial analysis of Aditxt, Inc. (ADTX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Aditxt, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Nandan Denim Limited (NDL.NS) Income Statement Analysis – Financial Results
- Azarga Metals Corp. (EUUNF) Income Statement Analysis – Financial Results
- China Everbright Environment Group Limited (0257.HK) Income Statement Analysis – Financial Results
- Adavale Resources Limited (ADRLF) Income Statement Analysis – Financial Results
- Adex Mining Inc. (ADXDF) Income Statement Analysis – Financial Results
Aditxt, Inc. (ADTX)
About Aditxt, Inc.
Aditxt, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune mapping and reprogramming. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. Aditxt, Inc. has a license agreement with Loma Linda University and Leland Stanford Junior University. The company was formerly known as ADiTx Therapeutics, Inc. and changed its name to Aditxt, Inc. in July 2021. Aditxt, Inc. was incorporated in 2017 and is headquartered in Richmond, Virginia.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|
| Revenue | 645.18K | 933.72K | 105.03K | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 756.84K | 766.78K | 77.98K | 17.77K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -111.66K | 166.94K | 27.06K | -17.77K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | -17.31% | 17.88% | 25.76% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 7.07M | 7.27M | 5.04M | 937.97K | 175.44K | 525.00K | 0.00 |
| General & Administrative | 18.61M | 15.99M | 22.08M | 7.85M | 5.69M | 5.04M | 851.94K |
| Selling & Marketing | 269.28K | 1.85M | 334.98K | 81.99K | 551.00 | 39.84K | -638.96K |
| SG&A | 18.88M | 17.84M | 22.42M | 7.93M | 5.70M | 5.08M | 212.99K |
| Other Expenses | 0.00 | 58.96K | 14.42M | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 25.95M | 25.10M | 27.46M | 8.87M | 5.87M | 5.61M | 212.99K |
| Cost & Expenses | 26.71M | 25.87M | 27.54M | 8.87M | 5.87M | 5.61M | 212.99K |
| Interest Income | 10.17K | 57.35K | 3.10K | 563.00 | 1.93K | 0.00 | 0.00 |
| Interest Expense | 6.39M | 2.29M | 1.94M | 310.08K | 1.93K | 79.77K | 0.00 |
| Depreciation & Amortization | 542.58K | 535.98K | 476.24K | 17.77K | 5.87M | 5.61M | 851.94K |
| EBITDA | -25.46M | -24.83M | -43.96M | -8.85M | 45.00K | 0.00 | 638.96K |
| EBITDA Ratio | -3,945.89% | -2,600.78% | -25,663.68% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -26.06M | -24.94M | -27.43M | -8.87M | -5.87M | -5.61M | -212.99K |
| Operating Income Ratio | -4,039.58% | -2,670.64% | -26,120.04% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -6.33M | -2.17M | -4.44M | -277.02K | 43.07K | -79.77K | 0.00 |
| Income Before Tax | -32.39M | -27.65M | -46.37M | -9.15M | -5.83M | -5.69M | -212.99K |
| Income Before Tax Ratio | -5,020.40% | -2,961.28% | -44,148.91% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 543.94K | 1.94M | 310.08K | 1.93K | -161.14K | -851.94K |
| Net Income | -32.38M | -28.19M | -48.31M | -9.46M | -5.83M | -5.69M | -212.99K |
| Net Income Ratio | -5,018.92% | -3,019.53% | -45,994.56% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -108.15 | -608.04 | -5.06K | -1.46K | -2.25K | -2.90K | -82.35 |
| EPS Diluted | -108.15 | -608.04 | -5.06K | -1.46K | -2.25K | -2.90K | -82.35 |
| Weighted Avg Shares Out | 302.36K | 46.37K | 9.55K | 6.49K | 2.59K | 1.96K | 2.59K |
| Weighted Avg Shares Out (Dil) | 302.36K | 46.37K | 9.55K | 6.49K | 2.59K | 1.96K | 2.59K |
CORRECTING and REPLACING Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--In the first and second paragraphs, shares of common stock should read: 1.6 million, (instead of 1.65 million). Second paragraph, second sentence, the conversion price of the Series C-1 Convertible Preferred Stock should read: $2.595 per share...
Aditxt Announces Pricing of $4.2 Million Private Placement Priced At-The-Market under Nasdaq Rules
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into securities purchase agreements for the purchase and sale of an aggregate...
Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)
MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced that it has entered into a definitive arrangement agreement ("Arrangement Agreement") to acquire Appili Therapeutics Inc....
Evofem Reports $18.2 million of Phexxi Net Product Sales in 2023
-- Third Consecutive Year of Phexxi Net Sales Growth -- -- Total Operating Expense Reduced 64% from 2022 Levels -- -- Sales and marketing expense as a percentage of net sales was 54% for the fourth quarter of 2023, the...
Evofem Negotiates Improved Rebate for Hormone-Free "In the Moment" Contraceptive PHEXXI with Medi-Cal
— Medi-Cal serves more than 15.4 million Californians — — 7.4% improvement in Phexxi rebate to take effect July 1, 2024 — SAN DIEGO , March 20, 2024 /PRNewswire/ -- Commercial-stage women's health innovator Evofem Biosciences, Inc. (OTCQB: EVFMD) today announced that...
For Women Using GLP-1 Receptor Agonists who take Oral Birth Control Pills, Hormone-Free Phexxi Contraceptive Gel is a Logical Solution to Help Prevent Unintended Pregnancy
-- New weight loss drugs like Ozempic, Wegovy and Zepboundmay make oral birth control pills less effective at certain points -- SAN DIEGO , March 7, 2024 /PRNewswire/ -- Use of GLP-1 receptor agonists, or GLP-1s, is skyrocketing in the United States,...
Evofem Biosciences Announces Strong Preliminary Results, Record Phexxi Net Sales for Fiscal 2023
Evofem Delivers Third Consecutive Year of Phexxi Net Sales Growth Total Operating Expense Reduced More Than 60% from 2022 Levels SAN DIEGO , Feb. 1, 2024 /PRNewswire/ -- Evofem Biosciences, Inc. (OTCQB: EVFM) today announced strong preliminary, unaudited results for...
Aditxt, Inc. Acquires Proprietary Electroencephalography (EEG) Brain Monitoring Technologies and Devices, Including NeuroCap™ and NeuroEEG™ for Telehealth and Tele-neurology Applications
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announced the acquisition of a portfolio of EEG brain monitoring technologies and devices formerly owned by Brain Scientific,...
Aditxt, Inc.'s Subsidiary Pearsanta, Inc. Acquires MDNA Life Sciences Inc.'s Proprietary Mitomic™ Testing Platform Pioneering Early Disease and Cancer Detection in a Transaction Valued at Approximately $25 Million
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (“Aditxt” or the “Company”) (NASDAQ: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, today announces that the Company and its subsidiary, Pearsanta, Inc. (“Pearsanta”), has acquired MDNA Life Sciences Inc.'s (“MDNA”) proprietary,...
Aditxt Announces Closing of $6.0 Million Private Placement Priced At-The-Market under Nasdaq Rules
RICHMOND, Va.--(BUSINESS WIRE)--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), an innovation company developing and commercializing technologies with a focus on monitoring and modulating the immune system, today announced that it has closed its previously announced private placement for the...
Source: https://incomestatements.info
Category: Stock Reports